-+ 0.00%
-+ 0.00%
-+ 0.00%

ASTELLAS AND AUDAX BIOSCIENCES ENTER EXCLUSIVE OPTION AND LICENSE AGREEMENT FOR DAX-044, A NOVEL IMMUNE-TARGETED IL-12 ANTIBODY-CYTOKINE FUSION FOR IMMUNO-ONCOLOGY

Reuters·10/27/2026 23:30:03

Please log in to view news